- Home
- MSD vs MRSN Comparison
MSD vs MRSN Comparison
Compare MSD & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSD | MRSN |
|---|---|---|
| Founded | 1993 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.4M | 138.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MSD | MRSN |
|---|---|---|
| Price | $7.30 | $28.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.38 |
| AVG Volume (30 Days) | ★ 70.2K | 63.2K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,180,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.11 | $5.21 |
| 52 Week High | $7.46 | $51.50 |
Technical Indicators
Market Signals| Indicator | MSD | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 86.30 |
| Support Level | $7.35 | $27.31 |
| Resistance Level | $7.46 | $29.20 |
| Average True Range (ATR) | 0.04 | 0.56 |
| MACD | 0.00 | -0.52 |
| Stochastic Oscillator | 0.29 | 91.67 |
Price Performance
Historical ComparisonAbout MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.